Urogen Pharma (URGN) Stock Price
Urogen Pharma Price
Over the last 9 years Urogen Pharma grew revenue by 22.6% annually, reaching 109.79 M USD. For Urogen Pharma, the net margin of -139.8% is up versus -230.7% a few years ago. The consensus 12-month price target for Urogen Pharma is 50.00 USD, about 22.9% above where the stock trades today. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus.
Urogen Pharma stock price
Urogen Pharma business model & stock analysis
Frequently asked questions about Urogen Pharma
The business model of Urogen Pharma Ltd revolves around developing and commercializing innovative therapies for various urological conditions. Urogen Pharma primarily focuses on developing novel treatments for patients with urinary tract cancers and other urological disorders. The company utilizes its proprietary technology platform to create locally administered, precision medicines that aim to deliver targeted therapy where it is needed most while minimizing side effects. By leveraging its expertise in urology and utilizing advanced scientific techniques, Urogen Pharma strives to improve patient outcomes and quality of life by providing effective and tailored treatment options for urological conditions.
Urogen Pharma Ltd is primarily active in the pharmaceutical industry.
The main competitors of Urogen Pharma Ltd in the market include various pharmaceutical companies that specialize in the same therapeutic areas. Some notable competitors are Company A, Company B, and Company C. These companies also develop and market pharmaceutical products for similar indications as Urogen Pharma Ltd. However, Urogen Pharma Ltd distinguishes itself through its unique approach to drug development and its focus on innovation. Despite the competition, Urogen Pharma Ltd strives to maintain its position as a leading player in the market by continuously advancing its pipeline and delivering high-quality products to patients.
Urogen Pharma Ltd is a pharmaceutical company specializing in developing innovative therapies for urologic conditions. Founded in 2004, the company is headquartered in Israel. Urogen Pharma is dedicated to improving patients' lives by providing novel treatment options in the field of urology. With a focus on urothelial cancer and urinary tract infections, Urogen Pharma's research and development efforts aim to address unmet medical needs. The company has achieved significant milestones, including the approval of their first therapy, Jelmyto, by the U.S. Food and Drug Administration in 2020. Urogen Pharma continues to expand its pipeline and collaborate with renowned scientific and medical professionals to transform urologic care.
Urogen Pharma Ltd has achieved several significant milestones. The company successfully received FDA approval for its innovative drug, UGN-101, which offers a promising treatment option for patients with low-grade upper tract urothelial cancer. Urogen has also expanded its product portfolio and secured major collaborations with renowned pharmaceutical companies. In addition, the company has demonstrated strong financial performance, with consistent revenue growth and strategic investments in research and development. Urogen Pharma Ltd's dedication to innovation and commitment to improving patient outcomes have positioned the company as a leader in the pharmaceutical industry.
Urogen Pharma Ltd is primarily present in the United States, with its headquarters located in Princeton, New Jersey. The company focuses on developing innovative treatments for urological diseases and cancers. Urogen Pharma Ltd has a strong presence in various regions of the United States, including major cities like New York, Chicago, and Los Angeles. With their commitment to improving patient outcomes, Urogen Pharma Ltd continues to expand its reach and collaborate with healthcare professionals and organizations nationwide.
Urogen Pharma Ltd is a biopharmaceutical company committed to advancing innovative therapies for urological conditions. With a strong dedication to improving patients' lives, Urogen Pharma focuses on developing novel treatments that address significant unmet medical needs. The company's corporate philosophy revolves around excellence, integrity, and scientific rigor. By harnessing cutting-edge technology and expertise, Urogen Pharma strives to deliver transformative solutions to patients worldwide. With its unwavering commitment to scientific advancement and patient-centric approach, Urogen Pharma continues to drive progress in the field of urology.
Analysts currently set an average price target of 53.40 USD for the Urogen Pharma stock (median: 50.00 USD), implying +28.9 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Urogen Pharma stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Urogen Pharma to generate revenue of 322.21 M USD and earnings per share of -0.22 USD.
Converted at the current exchange rate, the Urogen Pharma share trades at 36.17 EUR (40.70 USD).
The Urogen Pharma share (URGN) is listed on 3 stock exchanges, including: NASDAQ (URGN), London (0XOD.L), Frankfurt (UR8.F).
Urogen Pharma Ltd is a biopharmaceutical company that specializes in developing novel therapeutics for urological and oncological diseases. The company is based in the USA and has a global network of research and development partners. Urogen Pharma's business model includes several divisions, including research and development, manufacturing, and distribution of innovative drugs. The company specializes in developing drugs tailored to the needs of urological and oncological patients. The product range currently includes two preparations: Jelmyto™ and UGN-102. Jelmyto™ is the first and only intravesical chemotherapeutic for the treatment of superficial, non-muscle invasive tumors of the ureter. The treatment of ureteral tumors is difficult as they are typically challenging to reach and chemotherapy is usually ineffective for treating deep-seated tumors. Jelmyto™ works through direct intra-ureteral instillation and has proven to be highly effective in reducing tumor burden. UGN-102 is an innovative drug for the treatment of bladder cancer based on extensive research. The active ingredient is injected directly into the bladder and aims to destroy cancer cells without affecting healthy cells. UGN-102 is currently in Phase 3 clinical trials and has the potential to be a groundbreaking new treatment option for bladder cancer patients. In addition to product development, Urogen Pharma also invests in the manufacturing and distribution of its drugs. The company has agreements with leading contract manufacturing organizations for the production of its products and collaborates with some of the world's leading hospitals to distribute its products. Urogen Pharma's business model is based on ongoing development and innovation of new therapies for urological and oncological diseases. The company relies on close collaboration with leading research institutions and investments in the manufacturing and distribution of its products to achieve its vision of a better patient experience.
The expected revenue of Urogen Pharma is 322.21 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Urogen Pharma is -10.77 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Urogen Pharma is currently -186.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Urogen Pharma stock.
The price-to-sales ratio (P/S) of Urogen Pharma is currently 6.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Urogen Pharma stock.
The Eulerpool Quality Score for Urogen Pharma is 3/10.
The ISIN of Urogen Pharma is IL0011407140. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Urogen Pharma is A2DTCV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Urogen Pharma is URGN. The ticker symbol is used to trade Urogen Pharma shares on the stock exchange.
Urogen Pharma stock
Urogen Pharma Peer Group
Urogen Pharma Ticker
Urogen Pharma FIGI
All fundamentals and in-depth analysis of Urogen Pharma
Our stock analysis for Urogen Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Urogen Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.